Fat Loss & Metabolic

GLP-1 family analogs and metabolic peptides studied for appetite, glucose handling and body composition. 23 profiles, 7 sourceable from N1 Aminos.

AOD-9604

AOD 9604 · Tyr-hGH fragment 177-191

from $45.00

AOD-9604 is a fat-burning peptide that tricks your body into breaking down stored fat more efficiently, kind of like giving your metabolism a boost. It’s derived from human growth hormone but was specifically designed to avoid the side effects that regular growth hormone can cause.

Bone, Joint & Connective TissueMetabolic & Weight Management
Route
Subcutaneous
Dose
200 mcg – 500 mcg
Cycle
8–12 weeks

Cagrilintide

NN9838 (Novo Nordisk development code) · AM833 (development designation)

from $55.00

Cagrilintide is a next-generation weight-loss peptide engineered to control your appetite at the brain level, making you feel satisfied on less food without the jittery, nauseous side effects of older diet drugs. Unlike GLP-1 medications like semaglutide that target one appetite pathway, Cagrilintide activates amylin receptors—a different system your brain uses to know when you’re full and should stop eating.

Metabolic & Weight Management
Route
Subcutaneous
Dose
300 mcg – 1.2 mg
Cycle
Long-term management focus

MOTS-c

from $39.00

MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) is a mitochondrial-derived hormone peptide discovered to be released during exercise that awakens your cells’ power generators to burn fuel more efficiently, build muscle faster, and resist aging at the metabolic level. This 16-amino acid “mitokine” transfers to your cell nucleus during metabolic stress to activate protective genes, simultaneously boosting glucose uptake into muscles via AMPK activation, reducing inflammation, and protecting your heart and brain from oxidative damage—essentially molecular exercise in a syringe.

Metabolic & Weight ManagementMitochondrial & Energy Support
Route
Subcutaneous
Dose
200 mcg – 1 mg
Cycle
8–12 weeks

Retatrutide

from $59.00

Retatrutide is the first triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously to deliver superior weight loss and metabolic improvement exceeding any single or dual-agonist therapy—achieving 24.2% weight loss (approximately 50+ pounds) in individuals with obesity over 48 weeks and 16.9% in those with type 2 diabetes, with hepatic steatosis resolution in 85% of participants.

Metabolic & Weight Management
Route
Subcutaneous
Dose
2 mg – 12 mg
Cycle
Titrate every 4 weeks

Semaglutide

from $29.00

Semaglutide is a GLP-1 receptor agonist peptide that suppresses appetite, increases satiety, and improves glucose metabolism for pharmaceutical-grade weight loss and blood sugar control, achieving average weight loss of 15-18% body weight (30-40+ pounds) over 6 months in individuals with obesity or diabetes through sustained once-weekly injections or oral dosing. FDA-approved for both type 2 diabetes (as Ozempic) and weight management (as Wegovy), it outperforms all prior GLP-1 agonists including liraglutide with superior efficacy and sustained action.

Metabolic & Weight Management
Route
Subcutaneous
Dose
250 mcg – 2.4 mg
Cycle
Long-term management involves titrating to maintenance

Tesamorelin

Tesamorelin acetate · GHRH(1-44)

from $69.00

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to release its own growth hormone, achieving FDA-approved clinical efficacy for HIV-associated lipodystrophy with 15-20% visceral adipose tissue (VAT) reduction over 26 weeks—preferentially targeting dangerous abdominal fat while preserving subcutaneous fat and lean muscle mass, a metabolic selectivity unique among weight loss therapies.

Growth Hormone OptimizationMetabolic & Weight Management
Route
Subcutaneous
Dose
1 mg – 2 mg
Cycle
12–26 weeks

Tirzepatide

LY3298176 · Tilpotide

from $29.00

Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide combining glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to deliver superior weight loss and metabolic improvement versus single-agonist therapy, achieving 20.9% weight loss (40-50+ pounds) over 18 months with HbA1c reductions of 2.58% in type 2 diabetes—the most potent single metabolic agent currently available.

Metabolic & Weight Managementblend
Route
Subcutaneous
Dose
2.5 mg – 7.5 mg
Cycle

5-Amino-1MQ

5-amino-1-methylquinolinium · NNMTi

reference

5-Amino-1MQ is a special tiny molecule that acts like a helper in your body, targeting fat storage and energy use. Imagine it as a smart switch that turns down an enzyme called NNMT, which normally slows your metabolism and helps fat cells grow.

Anti-Aging & LongevityMetabolic & Weight Management
Route
Subcutaneous
Dose
2.5 mg – 5 mg
Cycle
10–20 days (based on a single 50 mg vial)

Adipotide (FTPP)

FTPP · Adipotide

reference

Research Goal: Investigating the induction of fat loss through targeted destruction of blood vessels supplying white adipose tissue.

Metabolic & Weight Management
Route
Subcutaneous
Dose
5 mcg – 20 mcg
Cycle
21–28 days; monitoring of renal markers is standard

AICAR

Acadesine · AICA-Riboside

reference

AICAR is an exercise-mimicking peptide that tricks your body into workout mode without moving a muscle. It activates a pathway called AMPK, which ramps up fat burning, boosts endurance, and improves heart health—like a molecular personal trainer.

Metabolic & Weight ManagementMitochondrial & Energy Support
Route
Subcutaneous
Dose
1 mg – 3 mg
Cycle
8–12 weeks

Carnitine

reference

Carnitine (L-carnitine) is a quaternary ammonium compound facilitating long-chain fatty acid transport into mitochondria for β-oxidation, increasing fat utilization by 20-50% during exercise while sparing glycogen and reducing lactate accumulation—essential for energy production in cardiac/skeletal muscle and preventing carnitine deficiency syndromes.[conversation context] Therapeutic doses (2-4g daily) enhance fat loss, exercise recovery, and insulin sensitivity in metabolic disorders.

Metabolic & Weight ManagementMitochondrial & Energy Support
Route
Subcutaneous
Dose
50 mg – 100 mg
Cycle
8–12 weeks

HGH Fragment 176-191

reference

HGH Fragment 176-191 is the isolated fat-burning region of human growth hormone, engineered specifically to target stubborn fat while avoiding the water retention, insulin resistance, and muscle-loss side effects of full GH. This 16-amino-acid sequence was identified as the exact region responsible for lipolysis—fat cell breakdown—making it remarkably selective for fat loss without systemic hormonal disruption.

Metabolic & Weight Management
Route
Subcutaneous
Dose
100 mcg – 300 mcg
Cycle
8–12 weeks

HGH Fragment, CJC-1295 (No DAC), Ipamorelin

No DAC · HGH Fragment 176-191

reference

This triple stack—HGH Fragment 176-191 for targeted fat loss, CJC-1295 (No DAC) for natural GH pulses, and Ipamorelin for clean amplification—creates comprehensive body recomposition by burning stubborn fat while preserving and building lean muscle. The Fragment mimics growth hormone’s fat-mobilizing region, accelerating lipolysis especially in the abdomen without affecting blood sugar.

Growth Hormone OptimizationMetabolic & Weight Managementblend
Route
Subcutaneous
Dose
100 mcg – 200 mcg
Cycle
8–12 weeks

HGH Fragment, Modified GRF, Ipamorelin

HGH Fragment 176-191 · hGH Frag 176-191

reference

HGH Fragment 176-191 combined with Modified GRF (CJC-1295 No DAC) and Ipamorelin creates a triple-action body recomposition system that burns fat aggressively while preserving muscle and amplifying growth hormone at multiple levels. The Fragment targets the specific fat-burning region of growth hormone without affecting blood sugar or hormones, Modified GRF triggers natural pulsatile GH release mimicking your body’s youthful pattern, and Ipamorelin amplifies those pulses cleanly.

Growth Hormone OptimizationMetabolic & Weight Managementblend
Route
Subcutaneous
Dose
100 mcg – 500 mcg
Cycle
8–12 weeks

Mazdutide

reference

Mazdutide is China’s first approved dual GLP-1/glucagon receptor agonist for obesity, delivering 14.8% weight loss at 6mg weekly (48 weeks) via appetite reduction plus increased energy expenditure targeting liver, brain, and adipose remodeling—83% of patients achieve ≥5% loss versus 11.5% placebo, with 50.6% reaching ≥15%. Lilly/Innovent collaboration yields first-in-class GCG/GLP-1 synergy, enhancing fat oxidation beyond GLP-1 alone.

Metabolic & Weight Management
Route
Subcutaneous
Dose
2.5 mg – 5 mg
Cycle
8–12 weeks

Orforglipron

reference

Research Goal: Analyzing the efficacy of a small-molecule GLP-1RA for gastric emptying inhibition and satiety signaling via oral administration.

Metabolic & Weight Management
Route
Oral
Dose
12 mg – 45 mg
Cycle
Chronic administration for metabolic research

Pancragen

reference

Pancragen is a tetrapeptide bioregulator (Lys-Glu-Asp-Trp) that restores pancreatic cell function by penetrating cell membranes to reprogram DNA transcription patterns, specifically upregulating genes critical for pancreatic maturation (Ptf1a, Pdx1, Pax6) while suppressing apoptotic signals that destroy pancreatic cells. Research shows it reduces fasting glucose by up to 40%, normalizes insulin secretion dynamics, and improves glucose utilization efficiency—effects that persist weeks after treatment concludes, suggesting genuine gene expression resets rather than temporary suppression.

Metabolic & Weight ManagementOrgan-Specific Bioregulators
Route
Subcutaneous
Dose
1 mg – 2 mg
Cycle
10–20 days; typically repeated every 4–6 months

SLU-PP-332

reference

SLU-PP-332 is an oral estrogen-related receptor (ERR) agonist that mimics exercise at the molecular level, activating the same metabolic pathways as 30 minutes of intense cardio without requiring physical exertion—enabling metabolic transformation through gene expression alone. Preclinical studies show it reduces fat mass by 12% in diet-induced obesity models while preventing new fat gain (versus 5g gain in controls), dramatically improves glucose tolerance and insulin sensitivity, reverses hepatic steatosis (fatty liver disease), and reduces inflammatory markers in liver and adipose tissue—all without increasing physical activity or changing diet.

Metabolic & Weight ManagementMitochondrial & Energy Support
Route
Subcutaneous
Dose
1.25 mg
Cycle
Research cycles typically span 4–8 weeks

Survodutide

reference

Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist engineered for superior obesity treatment, achieving 15-20% weight loss over 46 weeks through synergistic appetite suppression (GLP-1) and energy expenditure increase (glucagon), outperforming semaglutide in preclinical models with significant waist circumference and BMI reductions at doses >2mg weekly. Phase 2 trials confirm dose-dependent efficacy, with higher doses (>4.5mg) yielding maximal fat loss while preserving lean mass.

Metabolic & Weight Management
Route
Subcutaneous
Dose
1.2 mg – 4.8 mg
Cycle

Tesamorelin, CJC-1295 (No DAC), Ipamorelin

No DAC

reference

This triple stack synergistically maximizes visceral fat reduction through Tesamorelin’s targeted abdominal lipolysis (15% waist circumference reduction in HIV lipodystrophy), CJC-1295’s sustained GH pulsatility (3-5x baseline elevation over 6-8 hours), and Ipamorelin’s clean GH amplification without cortisol/prolactin spikes—achieving superior IGF-1 increases (up to 200%) and metabolic optimization versus dual therapies. Tesamorelin selectively mobilizes trunk fat via hypothalamic GH axis stimulation, complemented by CJC-1295’s half-life extension and Ipamorelin’s pituitary synergy.

Growth Hormone OptimizationMetabolic & Weight Managementblend
Route
Subcutaneous
Dose
100 mcg – 1 mg
Cycle
12–26 weeks

Tesamorelin, Ipamorelin

reference

Tesamorelin paired with Ipamorelin targets visceral fat obliteration through Tesamorelin’s specific trunk adipose reduction (1.3kg fat mass loss over 26 weeks) amplified by Ipamorelin’s selective GH release (no appetite/cortisol elevation), creating sustained IGF-1 elevation for metabolic and anabolic benefits without DAC-related prolongation risks. Tesamorelin’s FDA-approved HIV lipodystrophy efficacy translates to general visceral fat targeting, enhanced by Ipamorelin’s clean secretagogue profile.

Growth Hormone OptimizationMetabolic & Weight Managementblend
Route
Subcutaneous
Dose
1 mg
Cycle
12–26 weeks

Tesofensine

Tesofensine free base · NS-2330

reference

Research Goal: Analyzing the suppression of appetite and increase in resting energy expenditure through the modulation of neurotransmitter reuptake in the hypothalamus.

Cognitive & Neurological HealthMetabolic & Weight Management
Route
Oral
Dose
250 mcg – 1 mg
Cycle
12–24 weeks

TRH Thyrotropin (Protirelin)

Protirelin

reference

Research Goal: Analyzing the acute thyroid-stimulating hormone (TSH) response and the neuroprotective potential of TRH in central nervous system research.

Growth Hormone OptimizationMetabolic & Weight Management
Route
Subcutaneous
Dose
200 mcg – 1 mg
Cycle
Short pulses only; chronic use can desensitize TSH receptors
Where to source

Research compounds with a paper trail.

N1 Aminos tests every batch at an independent lab, ships tracked in 3–5 days, and publishes certificates of analysis on request.

Shop N1 Aminos →

Code DOSING15 · 15% off first order

Where to track

Never miss a dose or a cycle end.

StackTracker turns any protocol on this site into a daily brief with one-tap logging, half-life graphs and lab-result tracking.

Start a free trial →
Ask the advisor